A clinical case of treating of a patient with melanoma using checkpoint inhibitor pembolizumab (anti-PD-1 monoclonal antibody)
Summary. In article we present clinical case of patient with metastatic melanoma. Patient was treated with immune checkpoint inhibitor pembrolizumab. Dosage of Keytruda was 2 mg/kg (200 mg total dose) every 3 weeks. We discuss observation and treatment tactics of this patient. We continue pembrolizumab treatment and propose stereotactic radiation therapy of solitary metastasis in scapula.
Leave a comment